Distinct from other markers such as CD123 and CD56, which manifest across a spectrum of hematologic malignancies, CD303 is predominantly expressed on pDCs, thereby providing a potent diagnostic tool for identifying malignant pDCs in BPDCN [58,59,60]. Here, CLEC4C is linked to hematologic disorder.